These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3391862)

  • 21. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.
    Laille E; Patel M; Jones SF; Burris HA; Infante J; Lemech C; Liu L; Arkenau HT
    J Clin Pharmacol; 2015 Dec; 55(12):1378-85. PubMed ID: 26053962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women.
    Blode H; Zeun S; Parke S; Zimmermann T; Rohde B; Mellinger U; Kunz M
    Contraception; 2012 Oct; 86(4):337-44. PubMed ID: 22445438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.
    Mallolas J; Sarasa M; Nomdedeu M; Soriano A; López-Púa Y; Blanco JL; Martínez E; Gatell JM
    HIV Med; 2007 Mar; 8(2):131-4. PubMed ID: 17352770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist.
    Ogilvie BW; Torres R; Dressman MA; Kramer WG; Baroldi P
    J Clin Pharmacol; 2015 Sep; 55(9):1004-11. PubMed ID: 25851638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
    Einolf HJ; Zhou J; Won C; Wang L; Rebello S
    Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
    Stroh M; Palcza J; McCrea J; Marsilio S; Breidinger S; Panebianco D; Johnson-Levonas A; Kraft WK; Orford K; Murphy G; Agrawal N; Trucksis M; Wagner JA; Iwamoto M
    Cancer Chemother Pharmacol; 2012 May; 69(5):1247-53. PubMed ID: 22290273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
    Martin P; Gillen M; Millson D; Oliver S; Brealey C; Grossbard EB; Baluom M; Lau D; Sweeny D; Mant T; Craven K
    Drugs R D; 2016 Mar; 16(1):81-92. PubMed ID: 26739683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
    Machiels JP; Staddon A; Herremans C; Keung C; Bernard A; Phelps C; Khokhar NZ; Knoblauch R; Parekh TV; Dirix L; Sharma S
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):729-37. PubMed ID: 25100135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic interactions with rifampicin : clinical relevance.
    Niemi M; Backman JT; Fromm MF; Neuvonen PJ; Kivistö KT
    Clin Pharmacokinet; 2003; 42(9):819-50. PubMed ID: 12882588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transporter-mediated drug interactions: clinical implications and in vitro assessment.
    Lin JH
    Expert Opin Drug Metab Toxicol; 2007 Feb; 3(1):81-92. PubMed ID: 17269896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: an open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers.
    Piñeyro-López A; Pineyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez Silva M; Wacksman N; Lujàn Rangel R; de Lago A; Trejo D; Gonzàlez-de la Parra M; Namur S
    Clin Ther; 2006 Jan; 28(1):110-5. PubMed ID: 16490584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals.
    Moody DE; Walsh SL; Rollins DE; Neff JA; Huang W
    Clin Pharmacol Ther; 2004 Aug; 76(2):154-66. PubMed ID: 15289792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.
    Lehtinen T; Tolonen A; Turpeinen M; Uusitalo J; Vuorinen J; Lammintausta R; Pelkonen O; Scheinin M
    Biopharm Drug Dispos; 2013 Oct; 34(7):387-95. PubMed ID: 23852652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.
    Yamashita SK; Ludwig EA; Middleton E; Jusko WJ
    Clin Pharmacol Ther; 1991 May; 49(5):558-70. PubMed ID: 1827622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients.
    Sriwiriyajan S; Mahatthanatrakul W; Ridtitid W; Jaruratanasirikul S
    Eur J Clin Pharmacol; 2007 May; 63(5):479-83. PubMed ID: 17345073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin.
    Conte JE; Golden JA; Kipps JE; Lin ET; Zurlinden E
    Clin Pharmacokinet; 2004; 43(6):395-404. PubMed ID: 15086276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacokinetics of oral rifampicin in AIDS patients.
    Jaruratanasirikul S
    J Med Assoc Thai; 1998 Jan; 81(1):25-8. PubMed ID: 9470318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.